Skip to content

Clinical Evaluation of LightSheer Duet 805nm HS Handpiece

Clinical Evaluation of LightSheer Duet 805nm HS Handpiece

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01801202
Enrollment
21
Registered
2013-02-28
Start date
2013-02-28
Completion date
2014-11-30
Last updated
2015-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hair Removal

Brief summary

* The study will re-confirm that the LightSheer Duet HS 805 nm handpiece is safe for removal of unwanted hair, and will result in hair removal and permanent hair count reduction. * Twenty (20)subjects, Fitzpatrick Skin Type I-IV will be included in a single site. * Each subject will receive five treatments at four to six week intervals and return for follow-up visits at three and six months after the last treatment for evaluation of the treated areas.

Interventions

DEVICELightSheer Duet HS handpiece

The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).

Sponsors

Lumenis Be Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Able to read, understand and provide written Informed Consent; 2. Healthy adult, male or female, 18 years of age or older with skin type I-IV; 3. Having a suitable treatment area for hair removal; 4. Able and willing to comply with the treatment/follow-up schedule and requirements; 5. Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control at least three months prior to enrollment and throughout the course of the study.

Exclusion criteria

1. Pregnant, expectation of pregnancy, postpartum or nursing (\<6 months); 2. Hormonal disorders that may affect hair growth; 3. Immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications; 4. Livedo reticularis; 5. Uncontrolled systemic diseases such as diabetes; 6. Active infections in the treated area; 7. Dysplastic nevi; 8. Significant concurrent skin conditions or any inflammatory skin conditions; 9. Active cold sores, open lacerations or abrasions; 10. Chronic or cutaneous viral, fungal, or bacterial diseases; 11. Current cancer; 12. History of skin cancer or pre-cancerous lesions at the treatment areas; 13. Use of Accutane™ (Isotretinoin) within the past six month; 14. Keloid formation in the treatment area; 15. Tattoos in the treatment area; 16. Bleeding coagulopathies or use of anticoagulants; 17. Auto-immune disorders; 18. Erythema ab igne, when identified treatments should be discontinued; 19. Photosensitivity disorder that can be exacerbated by laser or intense light; 20. Herpes simplex in the treatment area; 21. Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light; 22. Poor wound healing; 23. Sunburns; 24. Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a week) and during the course of the evaluation; 25. Prior skin treatment with laser or other devices on the same treated areas within the last six months prior to study enrollment or during the course of the study.

Design outcomes

Primary

MeasureTime frameDescription
Number of subjects with Adverse Events1 yearTo evaluate the safety of hair removal using the LightSheer Duet HS 805 nm handpiece
Hair count6 monts follow upTo verify hair removal and permanent hair reduction using the LightSheer Duet HS 805 nm handpiece

Secondary

MeasureTime frameDescription
Subject's comfort using VASBaseline, 4, 8, 12, 16 weeks;To evaluate subject's assessment of comfort associated with treatments
Asses subject's perception of improvement and satisfaction8, 16 weeks following baseline; 3 and 6 monts follow upTo evaluate subject's satisfaction with hair removal treatments and assessment of improvement using subject's questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026